{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:21:46Z","timestamp":1768980106310,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"vor","delay-in-days":735,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1111\/jth.15078","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T08:39:49Z","timestamp":1598863189000},"page":"3053-3060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["First\u2010in\u2010patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura"],"prefix":"10.1016","volume":"18","author":[{"given":"Zhenlei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengkui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiequn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1111\/jth.15078_bb0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2042098618769587","article-title":"Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety","volume":"9","author":"Gonzalez\u2010Porras","year":"2018","journal-title":"Ther Adv Drug Saf"},{"issue":"4 Suppl 5","key":"10.1111\/jth.15078_bb0015","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.seminhematol.2007.11.003","article-title":"Current options for the treatment of idiopathic thrombocytopenic purpura","volume":"44","author":"Arnold","year":"2007","journal-title":"Semin Hematol"},{"issue":"11","key":"10.1111\/jth.15078_bb0020","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1111\/jth.15078_bb0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bjh.14380","article-title":"Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia","volume":"176","author":"Yang","year":"2017","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1111\/jth.15078_bb0030","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1111\/jth.15078_bb0035","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.seminhematol.2019.09.001","article-title":"Mechanisms and therapeutic prospects of thrombopoietin receptor agonists","volume":"56","author":"Bussel","year":"2019","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1111\/jth.15078_bb0040","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.15078_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4137\/CMBD.S39643","article-title":"Advances in diagnosis and treatments for immune thrombocytopenia","volume":"9","author":"Nomura","year":"2016","journal-title":"Clin Med Insights Blood Disord"},{"issue":"16","key":"10.1111\/jth.15078_bb0050","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American society of hematology 2011 evidence\u2010based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1111\/jth.15078_bb0055","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"10.1111\/jth.15078_bb0060","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bcpt.12815","article-title":"Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO\u2010R agonist, in healthy individuals","volume":"121","author":"Zheng","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1111\/jth.15078_bb0065","first-page":"212","article-title":"Thrombopoietin receptor agonists: eltrombopag and romiplostim for the treatment of chronic immune thrombocytopenia purpura","volume":"23","author":"Atkinson","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"12","key":"10.1111\/jth.15078_bb0070","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40265-019-01159-0","article-title":"Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation","volume":"79","author":"Fattizzo","year":"2019","journal-title":"Drugs"},{"key":"10.1111\/jth.15078_bb0075","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/bloodadvances.2017010660","article-title":"Eltrombopag for use in children with immune thrombocytopenia","volume":"2","author":"Kim","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"10.1111\/jth.15078_bb0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF03190077","article-title":"A double\u2010site absorption model fits to pharmacokinetic data of repaglinide in man","volume":"25","author":"Liu","year":"2000","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1111\/jth.15078_bb0085","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/bdd.1843","article-title":"Therapeutic drug monitoring and pharmacokinetic compartmental analysis of sulpiride double\u2010peak absorption profile after oral administration to human volunteers","volume":"34","author":"Helmy","year":"2013","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"10.1111\/jth.15078_bb0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cmpb.2010.03.007","article-title":"Modelling the Double Peak Phenomenon in pharmacokinetics","volume":"104","author":"Godfrey","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"issue":"5","key":"10.1111\/jth.15078_bb0095","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1538-7836.2012.04695.x","article-title":"A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia","volume":"10","author":"Tomiyama","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"9664","key":"10.1111\/jth.15078_bb0100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double\u2010blind, placebo\u2010controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"issue":"22","key":"10.1111\/jth.15078_bb0105","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"issue":"9763","key":"10.1111\/jth.15078_bb0110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6\u2010month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15078","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15078","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622037461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622037461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:25:20Z","timestamp":1761535520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622037461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1538783622037461"],"URL":"https:\/\/doi.org\/10.1111\/jth.15078","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First\u2010in\u2010patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}